Breaking the mould-novel diagnostic and therapeutic strategies for invasive pulmonary aspergillosis in the immune deficient patient

Expert Review of Clinical Immunology

Volumn 10, Issue 6, 2014, Pages 771-780

  Thornton, Christopher R ^a  

^a UNIVERSITY OF EXETER   (United Kingdom)

Author keywords

bioimaging; hematological malignancy; invasive pulmonary aspergillosis; monoclonal antibody; PET MRI; radioimmunotherapy; stem cell transplant; vaccine

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; BETA GLUCAN; GALLIUM 68; GLIOTOXIN; IMMUNOGLOBULIN F(AB) FRAGMENT; MANNOPROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY JF5; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG; VORICONAZOLE; FUNGUS ANTIBODY;

ACREMONIUM; ACUTE GRANULOCYTIC LEUKEMIA; ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CANDIDA; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FUSARIUM; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOCOMPROMISED PATIENT; ISOTOPE LABELING; LUNG ASPERGILLOSIS; LUNG BIOPSY; LUNG LAVAGE; META ANALYSIS (TOPIC); NUCLEAR MAGNETIC RESONANCE IMAGING; PNEUMOCYSTIS; POINT OF CARE TESTING; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PROXIMITY LIGATION ASSAY; RADIOIMMUNOTHERAPY; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SACCHAROMYCES; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW (TOPIC); TRICHOSPORON; ANIMAL; ASPERGILLUS; COMMON VARIABLE IMMUNODEFICIENCY; IMMUNOLOGY; PULMONARY ASPERGILLOSIS; RADIOGRAPHY;

ANIMALS; ANTIBODIES, FUNGAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ASPERGILLUS; COMMON VARIABLE IMMUNODEFICIENCY; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; POSITRON-EMISSION TOMOGRAPHY; PULMONARY ASPERGILLOSIS;

EID: 84901054436     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/1744666X.2014.904747     Document Type: Review

References (92)

1. Kwon-Chung KJ, Sugui JA. Aspergillus fumigatus-what makes the species a ubiquitous human fungal pathogen. PLoS Pathog 2013;9(12):e1003743
2. Stevens DA, Kan VL, Judson MA, et al. Practice guidelines for diseases caused by Aspergillus Clin Infect Dis. 2000;30: 696-709
3. Schweer KE, Bangard C, Hekmat K, et al. Chronic pulmonary aspergillosis. Mycoses 2013. [Epub ahead of print]
4. Dagenais TRT, Keller NP. Pathogenesis of Aspergillus fumigatus in invasive aspergillosis. Clin Rev Microbiol 2009;22:447-65
5. Segal BH. Aspergillosis. N Engl J Med 2009;360:1870-84
6. Brown GD, Denning DW, Gow NAR, et al. Hidden killers: human fungal infections. Sci Transl Med 2012;4: 165rv13
7. Schrettl M, Bignell E, Kragl C, et al. Distinct roles for intra-and extracellular siderophores during Aspergillus fumigatus infection. PLoS Pathog 2007;3: e128
8. Blanoc JL, Hontecillas R, Bouza E, et al. Correlation between the elastase activity index and invasiveness of clinical isolates of Aspergillus fumigatus. J Clin Microbiol 2002;40:1811-13
9. Spikes S, Xu R, Nguyen CM, et al. Gliotoxin production in Aspergillus fumigatus contributes to host-specific differences in virulence. J Infect Dis 2008;197:479-86
10. Thornton CR. Detection of invasive aspergillosis. Adv Appl Microbiol 2010;70: 187-216
11. Thornton CR, Wills OE. Immunodetection of fungal and oomycete pathogens: established and emerging threats to human health, animal welfare and global food security. Crit Rev Microbiol 2013. [Epub ahead of print]
12. Thornton CR. Lateral-flow device for diagnosis of fungal infection. Curr Fungal Infect Rep 2013;7:244-51
13. Schwarzinger M, Sagaon-Teyssier L, Cabaret O. Performance of serum biomarkers for early detection of invasive aspergillosis in febrile, neutropenic patients: a multi-state model. PLoS One 2013;8: e65776
14. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organisation for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008;46:1813-21
15. Barnes R Directed therapy for fungal infections: focus on aspergillosis. J Antimicrob Chemother 2013;68:2431-4
16. Herbrecht R, Denning D, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408-15
17. Albarrag AM, Anderson MJ, Howard SJ, et al. Interrogation of related clinical pan-azole-resistant Aspergillus fumigatus strains: G138C, Y431C, and G434C single nucleotide polymorphisms in cyp51A, upregulation of cyp51A, and integration and activation of transposon Atf1 in the cyp51A promoter. Antimicrob Agents Chemother 2011;55:5113-21
18. Steinbach WJ. Are we there yet? Recent progress in the molecular diagnosis and novel antifungal targeting of Aspergillus fumigatus and invasive aspergillosis. PLoS Pathog 2013;9(10):e1003642
19. Patterson TF. Clinical utility and development of biomarkers in invasive aspergillosis. Trans Am Clin Climat Assoc 2011;122:174-83
20. Lin J-C, Li M, Xu W-M, et al. Identification of unique volatile compounds of Aspergillus fumigatus for potential diagnostic breath test by HS-SPME and GC-MS. J. Immunol Tech Infect Dis 2013;2:3
21. Latge J-P, Kobayashi H, Debeaupuis J-P, et al. Chemical and immunological characterization of the extracellular galactomannan of Aspergillus fumigatus. Infect Immun 1994;62(12):5424-33
22. Woo PCY, Chan C-M, Leung ASP, et al. Detection of cell wall galactomannoprotein Afmp1p in culture supernatants of Aspergillus fumigatus and in sera of aspergillosis patients. J Clin Microbiol 2002;40(11):4382-7
23. Woo PCY, Chong KTK, Leung ASP, et al. AFLMP1 encodes an antigenic cell wall protein in Aspergillus flavus. J Clin Microbiol 2003;41(2):845-50
24. McDonagh A, Federova ND, Crabtree J, et al. Sub-telomere directed gene expression during initiation of invasive aspergillosis. PLoS Pathog 2008;4(9):e1000154
25. Cairns T, Minuzzi F, Bignell E. The host-infecting fungal transcriptome. FEMS Microbiol Lett 2010;307:1-11
26. Park SY, Lee S-O, Choi S-H, et al. Aspergillus galactomannan antigen assay in bronchoalveolar lavage fluid for diagnosis of invasive pulmonary aspergillosis. J Infect 2010;61:492-8
27. Zou M, Tang L, Zhao S, et al. Systematic review and meta-analysis of detecting galactomannan in bronchoalveolar lavage fluid for diagnosing invasive aspergillosis. PLoS One 2012;7(8):e43347
28. Heng SC, Morrisey O, Chen SCA, et al. Utility of bronchoalveolar lavage fluid galactomannan alone or in combination with PCR for the diagnosis of invasive aspergillosis in adult hematology patients: a systematic review and meta-analysis. Crit Rev Microbiol 2013. [Epub ahead of print]
29. Thornton CR Development of an immunochromatographic lateral-flow device for rapid serodiagnosis of invasive aspergillosis. Clin Vaccine Immunol 2008; 15(7):1095-105
30. Yamamoto K, Tsuji T, Osawa T. Affinity chromatography of oligosaccharides and glycopeptides with immunobilized lectins. In: Walker JM, editor. The protein protocols handbook. Edition 2. Humana Press Inc; Totowa, NJ, USA: 2002. p. 917-31
31. Shibuya N, Goldstein IJ, Van Damme EJM, et al. Binding properties of a mannose specific lectin from the snowdrop (Galanthus nivalis) bulb. J Biol Chem 1988;263:728-34
32. Thornton CR, Wiederhold N, Najvar LK, et al. Successful detection of invasive pulmonary aspergillosis (IPA) using lateral-flow device (LFD) tests of bronchoalveolar lavage (BAL) fluids. Presented at: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 12-15 September 2010; Boston, MA, USA
33. Wiederhold NP, Thornton CR, Najvar LK, et al. Comparison of lateral flow technology and galactomannan and (1-3)-J3-D-glucan assays for detection of invasive pulmonary aspergillosis. Clin Vacc Immunol 2009;16: 1844-6
34. Wiederhold NP, Najvar LK, Bocanegra R, et al. Inter-laboratory and inter-study reproducibility of a novel lateral-flow device and the influence of antifungal therapy on the detection of invasive pulmonary aspergillosis. J Clin Microbiol 2013;51: 459-65
35. Thornton CR, Johnson G, Agrawal S. Detection of invasive pulmonary aspergillosis in haematological malignancy patients by using lateral-flow technology. J Vis Exp 2012;61:e3721
36. Hoenigl M, Koidl C, Duettman W, et al. Bronchoalveolar lavage lateral-flow device test for invasive pulmonary aspergillosis diagnosis in haematological malignancy and solid organ transplant patients. J Infect 2012;65:588-91
37. White PL, Parr C, Thornton C, et al. An evaluation of real-time PCR, galactomannan ELISA and a novel lateral-flow device for diagnosis of invasive aspergillosis. J Clin Microbiol 2013;51:1510-16
38. Held J, Schmidt T, Thornton CR, et al. Comparison of a novel Aspergillus lateral-flow device and the Platelia galactomannan assay for the diagnosis of invasive aspergillosis following haematopoietic stem cell transplantation. Infection 2013;41(6):1163-9
39. McCulloch E, Ramage G, Rajendran R, et al. Antifungal treatment affects the laboratory diagnosis of invasive aspergillosis. J Clin Pathol 2012;65:83-6
40. Yoshida M, Obayashi T, Iwama A, et al. Detection of plasma (1-3)-beta-D-glucan in patients with Fusarium, Trichosporon, Saccharomyces and Acremonium fungaemias. J Med Vet Mycol 1997;35: 371-274
41. Willinger B, Haase G. State-of-the-art procedures and quality management in diagnostic medical mycology. Curr Fungal Infect Rep 2013;7:260-72
42. Alexander BD, Smith PB, Davis RD, et al. The (1, 3)b-D-glucan test as an aid to early diagnosis of invasive fungal infections following lung transplantation. J Clin Microbiol 2010;48:4083-8
43. Acosta J, Catalan M, del Palacio-Perez-Medel A, et al. A prospective comparison of galactomannan in bronchoalveolar lavage fluid for the diagnosis of pulmonary invasive apsergillosis in medical patients under intensive care: comparison with the diagnostic performance of galactomannan and of (1!3)-b-D-glucan chromogenic assay in serum samples. Clin Microbiol Infect 2010;17:1053-60
44. Kawayama T, Fujiki R, Honda J, et al. High concentration of (1!3)-b-D-glucan in BAL fluid in patients with eosinophilic pneumonia. Chest 2003;123:1302-7
45. Litvintseva A, Lindsley MD, Gade L, et al. Utility of (1-3)-b-D-glucan testing for diagnostics and monitoring response to treatment during the multistate outbreak of fungal meningitis and other infections. Clin Infect Dis 2014;58:622-30
46. White PL, Bretagne S, Klingspor L, et al. Aspergillus PCR: one step closer to standardization. J Clin Microbiol 2010;49: 3842-8
47. Buess M, Cathomas G, Halter J, et al. Aspergillus-PCR in bronchoalveolar lavage for detection of invasive pulmonary aspergillosis in immunocompromised patients. BMC Infect Dis 2012;12: 237-44
48. Johnson GL, Bibby DF, Wong S, et al. A MIQE-compliant real-time PCR assay for Aspergillus detection. PLoS One 2012;7: e40022
49. Reinwald M, Hummel M, Kovalevskaya E, et al. Therapy with antifungals decreases the diagnostic performance of PCR for diagnosing invasive aspergillosis in bronchoalveolar lavage samples of patients with haematological malignancies. J Antimicrob Chemother 2012;67:2260-7
50. Weibrecht I, Leuchowius K-J, Clausson C-M, et al. Proximity ligation assays: a recent addition to the proteomics toolbox. Expert Rev Proteomics 2010;7(3): 401-9
51. Ke R, Nong RY, Frederiksson S, et al. Improving precision of proximity ligation assay by amplified single molecule detection. PLoS One 2013;8:e69813
52. Johnson GL, Shannon M, Thornton CR, et al. Proximity ligation assay for the sensitive specific and early diagnosis of invasive fungal disease. Mycoses 2013;56: 48-9
53. Gardiner DM, Waring P, Howlett BJ. The epipolythiodioxopiperazine (ETP) class of fungal toxins: distribution, mode of action, functions and biosynthesis. Microbiology 2005;151:1021-32
54. Sutton P, Newcombe NR, Waring P, et al. In vivo immunosuppressive activity of gliotoxin, a metabolite produced by human pathogenic fungi. Infect Immun 1994;62: 1192-8
55. Pardo J, Urban C, Galvez EM, et al. The mitochondrial protein Bak is pivotal for gliotoxin-induced apoptosis and a critical host factor of Aspergillus fumigatus virulence in mice. J Cell Biol 2006;174: 509-19
56. Spikes S, Xu R, Nguyen CK, et al. Gliotoxin production in Aspergillus fumigatus contributes to host-specific differences in virulence. J Infect Dis 2008;197:479-86
57. Sugui JA, Pardo J, Chang YC, et al. Gliotoxin is a virulence factor of Aspergillus fumigatus: gliP deletion attenuates virulence in mice immunosuppressed with hydrocortisone. Eukaryot Cell 2007;6: 1562-9
58. Domingo MP, Colmenarejo C, Mart́inez-Lostao L, et al. Bis(methyl) gliotoxin proves to be a more stable and reliable marker for invasive aspergillosis than gliotoxin and suitable for use in diagnosis. Diagn Microbiol Infect Dis 2012;73:57-64
59. Judenhofer MS, Cherry SR. Applications for preclinical PET/MRI. Semin Nucl Med 2013;43:19-29
60. Hasenberg M, Krappman S, Gunzer M. Visualizing immune responses in fungal infections: established and novel methods. In: Kurzai O, editor. Human fungal pathogens. 2nd Edition. The Mycota XII, Springer-Verlag; Berlin, Germany: 2013. p. 141-60
61. Haas H, Schoeser M, Lesuisse E, et al. Characterisation of the Aspergillus nidulans transporters for the siderophores enterobactin and triacetylfusarinine C. Biochem J 2003;371:505-13
62. Eisendle M, Schrettl M, Kragl C, et al. The intracellular siderophore ferricrocin is involved in iron storage, oxidative-stress resistance, germination, and sexual development in Aspergillus nidulans. Eukaryot Cell 2006;5:1596-603
63. Petrik M, Fransenn GM, Haas H, et al. Preclinical evaluation of two Ga-siderophores as potential radiopharmaceuticals for Aspergillus fumigatus infection imaging. Eur J Nucl Med Mol Imaging 2012;39:1175-83
64. Schrettl M, Kim HS, Eisendle M, et al. SreA-mediated iron regulation in Aspergillus fumigatus. Mol Microbiol 2008;70:27-43
65. Wang Y, Chen L, Liu X, et al. Detection of Aspergillus fumigatus pulmonary fungal infections in mice with (99m)Tc-labelled MORF oligomers targeting ribosomal RNA. Nucl Med Biol 2013;40:89-96
66. Dadachova E, Casadevall A. Cryptococcus neoformans as a model for radioimmunotherapy of infections. Interdiscip Perspect Infect Dis 2011;2011: 1-11
67. Dadachova E, Howell RW, Bryan RA, et al. Susceptibility of the human pathogenic fungi Cryptococcocus neoformans and Histoplasma capsulatum to y-radiation versus radioimmunotherapy with a-and [3-emitting radioisotopes. J Nucl Med 2004;45:313-20
68. Dadachova E, Burns T, Bryan RA. Feasibility of radioimmunotherapy of experimental pneumococcal infection. Antimicrob Agents Chemother 2004;48: 1624-9
69. Dadachova E, Bryan RA, Frenkel A, et al. Evaluation of acute hematologic and long-term pulmonary toxicities of radioimmunotherapy of Cryptococcus neoformans infection in murine models. Antimicrob Agents Chemother 2004;48: 1004-6
70. Dadachova E, Patel MC, Toussi S, et al. Targeted killing of virally infected cells by radiolabeled antibodies to viral proteins. PLOS Med 2006;3:e427
71. Dadachova E, Bryan RA, Apostolidis C. Interaction of radiolabeled antibodies with fungal cells and components of the immune system in vitro and during radioimmunotherapy for experimental fungal infection. J Infect Dis 2006;193: 1427-36
72. Bryan RA, Guimaraes AJ, Hopcraft S, et al. Toward developing a universal treatment for fungal disease using radioimmunotherapy targeting common fungal antigens. Mycopathologia 2012;173:463-71
73. Bryan RA, Jiang Z, Huang X, et al. Radioimmunotherapy is effective against high-inoculum Cryptococcus neoformans infection in mice and does not select for radiation-resistant cryptococcal cells. Antimicrob Agents Chemother 2009;53: 1679-82
74. Dadachova E, Nakouzi A, Bryan RA, et al. Ionizing radiation delivered by specific antibody is therapeutic against a fungal infection. Proc Natl Acad Sci USA 2003; 100(19):10942-7
75. Dadachova E, Casadevall A. Antibodies as delivery vehicles for radioimmunotherapy of infectious diseases. Expert Opin Drug Deliv 2005;2(6):1075-84
76. Nosanchuk JD, Dadachova E. Radioimmunotherapy of fungal diseases: the therapeutic potential of cytocidal radiation delivered by antibody targeting fungal cell surface antigens. Front Microbiol 2012; 2(283):1-6
77. Bryan RA, Jiang Z, Howell R, et al. Radioimmunotherapy is more effective than antifungal treatment in experimental cryptococcal infection. J Infect Dis 2010;202:633-7
78. Martinez LR, Bryan RA, Apostolidis C, et al. Antibody-guided alpha radiation effectively damages fungal biofilms. Antimicrob Agents Chemother 2006;50: 2132-6
79. MATHIAS. Available from: www.mathias-imaging.eu/index.php
80. Carvalho A, Cunha C, Iannitti RG, et al. Host defense pathways against fungi: the basis for vaccines and immunotherapy. Front Microbiol 2012;3(176):1-6
81. Cassone A, Casadevall A. Recent progress in vaccines against fungal diseases. Curr Opin Microbiol 2012;15:427-33
82. Spellberg B. Prospects for and barriers to a fungal vaccine. Expert Opin Biol Ther 2007;7(12):1785-8
83. Edwards JE. Fungal cell wall vaccines: an update. J Med Microbiol 2012;61: 895-903
84. Iannitti RG, Carvalho A, Romani L. From memory to antifungal vaccine design. Trends Immunol 2012;33:467-74
85. Torosantucci A, Bromuro C, Chiani P, et al. A novel glyco-conjugate vaccine against fungal pathogens. J Exp Med 2005;202:597-606
86. Cole GT, Hung C-Y, Sanderson SD, et al. Novel strategies to enhance vaccine immunity against coccidioidomycosis. PLoS Pathog 2013;9(12):e1003768
87. Spellberg B. Vaccines for invasive fungal infections. F1000 Med Rep 2011;3:13
88. Cenci E, Mencacci A, Bacci A, et al. T cell vaccination in mice with invasive pulmonary aspergillosis. J Immunol 2000;165:381-8
89. Bozza S, Gaziano R, Lipford GB, et al. Vaccination of mice against invasive aspergillosis with recombinant Aspergillus proteins and CpG oligodeoxynulceotides as adjuvants. Microbes Infect 2002;4:1281-90
90. Specht CA, Nong S, Dan JM, et al. Contribution of glycosylation to T cell responses stimulated by recombinant Cryptococcus neoformans mannoprotein. J Infect Dis 2007;196:796-800
91. Lam JS, Mansour MK, Specht CA, et al. A model vaccine exploiting fungal mannosylation to increase antigen immunogenicity. J Immunol 2005;175: 7496-503
92. Sheppard DC, Reig G, Chiang LY, et al. Novel inhalation murine model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2004;48:1908-11